Zhenglu Wang

Zhenglu Wang

Auto-generated profile, based on publicly available information

Zhenglu Wang

Organ Transplant Department, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
SZSai Zhang
Sai Zhang
SFShunli Fan
Shunli Fan
ZWZhenglu Wang
Zhenglu Wang
WHWen Hou
Wen Hou
TLTao Liu
Tao Liu
ZSZhongyang Shen
Zhongyang Shen
Transplant oncology is a newly emerging discipline integrating oncology, transplant medicine, and surgery and has brought malignancy treatment into a new era via transplantation. In this context, obtaining a drug with both immunosuppressive and antitumor effects can take into account the dual needs of preventing both transplant rejection and tumor recurrence in liver transplantation patients with malignancies. Capecitabine (CAP), a classic antitumor drug, has been shown to induce reactive oxygen species (ROS) production and apoptosis in tumor cells. Meanwhile, we have demonstrated that CAP can induce ROS production and apoptosis in T cells to exert immunosuppressive effects, but its underlying molecular mechanism is still unclear. In this study, metronomic doses of CAP were administered to normal mice by gavage, and the spleen was selected for quantitative proteomic and phosphoproteomic analysis. The results showed that CAP significantly reduced the expression of HSP90AB1 and SMARCC1 in the spleen. It was subsequently confirmed that CAP also significantly reduced the expression of HSP90AB1 and SMARCC1 and increased ROS and apoptosis levels in T cells. The results of in vitro experiments showed that HSP90AB1 knockdown resulted in a significant decrease in p‐Akt, SMARCC1, p‐c‐Fos, and p‐c‐Jun expression levels and a significant increase in ROS and apoptosis levels. HSP90AB1 overexpression significantly inhibited CAP‐induced T cell apoptosis by increasing the p‐Akt, SMARCC1, p‐c‐Fos, and p‐c‐Jun expression levels and reducing the ROS level. In conclusion, HSP90AB1 is a key target of CAP‐induced T cell apoptosis via Akt/SMARCC1/AP‐1/ROS axis, which provides a novel understanding of CAP‐induced T cell apoptosis and lays the experimental foundation for further exploring CAP as an immunosuppressant with antitumor effects to optimize the medication regimen for transplantation patients.